Related Experiment Video

Updated: Nov 27, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.2K

Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer

Rita Silva-Oliveira1,2, Filipa Ferreira Pereira3, Sara Petronilho1,4

  • 1Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.

Journal of Clinical Medicine
|December 5, 2020
PubMed
Abstract

Insights

Annexin A1 (ANXA1) shows potential as a prognostic marker for HER-2+ breast cancer patients, correlating with mortality and relapse. It may help stratify patients for treatment, though it did not predict trastuzumab response.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Breast Cancer Research

Background:

  • Trastuzumab is standard for HER-2+ breast cancer but has limitations, with many patients experiencing recurrence or lack of response.
  • New biomarkers are needed for better patient stratification in HER-2+ breast cancer.
  • Annexin A1 (ANXA1) has been implicated in trastuzumab resistance, and its expression may be linked to ARID1A loss.

Purpose of the Study:

  • To investigate the prognostic and predictive value of ARID1A and ANXA1 protein levels in HER-2+ breast cancer patients.
  • To assess the association between ARID1A, ANXA1 expression, and response to trastuzumab treatment.
  • To explore the role of these markers in patient outcomes, including mortality and relapse.

Main Methods:

  • Analysis of tissue samples from 215 HER-2+ breast cancer patients.
  • Assessment of ARID1A and ANXA1 protein expression using immunohistochemistry.
  • Correlation of protein expression levels with trastuzumab response and patient outcomes.

Main Results:

  • No inverse association was found between ARID1A and ANXA1 expression.
  • Higher ANXA1 expression was observed in HER-2+ (non-luminal) tumors compared to luminal B-like (HER-2+) tumors.
  • ARID1A and ANXA1 did not predict trastuzumab resistance, but ANXA1 expression was associated with increased breast cancer mortality and relapse.

Conclusions:

  • ANXA1 may serve as a valuable prognostic marker in HER-2+ breast cancer.
  • ANXA1 expression can help differentiate between HER-2+ (non-luminal) and luminal B-like (HER-2+) subtypes.
  • These findings may aid in stratifying HER-2+ breast cancer patients for tailored treatment strategies.
Keywords:
ANXA1ARID1Abiomarkersbreast cancertrastuzumab

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.5K
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K